Pearl Steinzor

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

Despite an overall decline in cancer-specific mortality, death rates from certain cancer types are rising among Asian American and Pacific Islander populations.

Smoking after a cancer diagnosis increases risk of mortality and a second cancer, study finds.

Report reveals growing divide between subsidized and unsubsidized enrollees.

Program yields largest savings in its history of more than $2.1 billion in 2023.

Leveraging Microsoft’s Azure OpenAI, Ontada streamlines oncology data analysis, reducing processing times by 85% to support clinical decisions and improve patient care for over 3000 oncologists across 30 states, according to Wanmei Ou, PhD, vice president of product, data analytics, and artificial intelligence (AI) at Ontada.

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

A new study assesses the prognostic accuracy of Predicting Risk of CVD EVENTs (PREVENT) equations for predicting cardiovascular disease (CVD) mortality in the US population.

A pioneering program targeting gut microbiome health significantly reduces cancer treatment side effects, enhancing patient well-being and resilience.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Groundbreaking proposal to expand contraception coverage under the ACA marks the most significant update in over 10 years.

The AMCP Nexus 2024 annual meeting covered a variety of hot health care topics impacting managed care pharmacy in the present and future.

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or influenza across Europe.

Experts explored the potential impacts of a Trump or Harris administration on the future of health care.

Industry experts explore the trends, variations, and implications of utilization management practices in specialty drug coverage.

Researchers explored innovative approaches to overcome barriers and drive sustainable biosimilar utilization.

Experts explored the latest trends, approvals, and pipeline developments in cell and gene therapies, rare disease, immunology, and more.

Experts discuss pricing, utilization, and health plan strategies to drive biosimilar uptake.

Experts reevaluate coverage policies and the financial impact of antiobesity medications based on updated clinical data and key utilization trends.

Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital, discusses therapies and management guidelines for patients with interstitial lung disease (ILD).

Io Hui, PhD, researcher at The University of Edinburgh, discusses challenges to implementing artificial intelligence in respiratory care.

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses the potential of tailored treatment strategies and the importance of smoking cessation.

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial infarction, and stroke.

Study findings reveals a 1-way relationship between cardiovascular disease and psoriasis, with no impact on other immune-mediated inflammatory diseases.

It is important to educate and bring awareness to childhood lymphoma, its symptoms, treatment options, and the need for support.

A new study highlights risk factors for hospitalization and severe illness among adults with respiratory syncytial virus (RSV) receiving care through the emergency department.

Hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome, and severe preeclampsia significantly elevate cardiovascular risk during delivery, study finds.

Adults who survived childhood cancer experience elevated fear that their primary cancer will recur or that a subsequent malignant neoplasm will develop, according to a new study.

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial.

Finerenone showed consistent cardiovascular benefits across heart failure populations, with enhanced efficacy in patients with worsening events.